Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D06EWO
|
||||
Former ID |
DAP000390
|
||||
Drug Name |
Gemtuzumab ozogamicin
|
||||
Synonyms |
Mylotarg (TN)
|
||||
Drug Type |
Antibody
|
||||
Therapeutic Class |
Anticancer Agents
|
||||
Company |
Wyeth Pharmaceuticals
|
||||
CAS Number |
CAS 220578-59-6
|
||||
SuperDrug ATC ID |
L01XC05
|
||||
Target and Pathway | |||||
KEGG Pathway | Hematopoietic cell lineage | ||||
References | |||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 541855 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6775). | ||||
Ref 535660 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
Ref 537216 | Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol. 2009 May;89(4):460-9. Epub 2009 Apr 10. | ||||
Ref 537245 | Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia. Turk J Pediatr. 2009 Jan-Feb;51(1):69-71. | ||||
Ref 537367 | Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol. 2009 Jun;37(6):755-66. | ||||
Ref 537432 | Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4(1):197-205. Epub 2009 May 14. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.